Baraliakos, X., Braun, J., Laurent, D., Baeten, D., van der Heijde, D., Sieper, J., . . . Hueber, W. (2013). Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)Baraliakos, X., et al. Long Term IL-17A Inhibition by Secukinumab Leads to Reduced Spinal Inflammation and Unchanged Fatty Lesions in Patients with Ankylosing Spondylitis. 2013.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.